Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.62 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.62 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.45 |
| ▸ | ERAP1 | Q9NZ08 | 5/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4203969 | 0.93 | HTR6 (0.65) | HTR6QRFPRMCL1ERAP1ERAP2 | |
| SCHEMBL4196178 | 0.90 | HTR6 (0.61) | HTR6QRFPRERAP1ERAP2TRIM24 | |
| SCHEMBL4209206 | 0.89 | HTR6 (0.75) | HTR6QRFPRMCL1LMNAALDH1A1 | |
| SCHEMBL4209165 | 0.86 | HTR6 (0.66) | HTR6QRFPRLMNAALDH1A1 | |
| SCHEMBL4204108 | 0.85 | HTR6 (0.62) | HTR6QRFPRLMNAALDH1A1 | |
| SCHEMBL4205768 | 0.85 | HTR6 (0.66) | HTR6QRFPRALDH1A1 | |
| SCHEMBL4213931 | 0.85 | HTR6 (0.56) | HTR6QRFPRLMNA | |
| SCHEMBL4201193 | 0.84 | HTR6 (0.47) | HTR6QRFPRMCL1ERAP1ERAP2 | |
| SCHEMBL4202388 | 0.83 | HTR6 (0.67) | HTR6QRFPRALDH1A1 | |
| SCHEMBL4207426 | 0.83 | HTR6 (0.65) | HTR6QRFPRLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030038-A1 | Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | claimed |
| EP-1263720-B1 | AZETIDINE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2009-06-03 | — | — | EP | disclosed |
| US-20090030038-A1 | Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| EP-1112251-B1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2003-05-07 | — | — | EP | disclosed |
| EP-1263720-A1 | AZETIDINE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001064632-A1 | AZETIDINE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030038-A1 | Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor | HTR6, HTR1A, HTR1D | HTR6 1/4885QRFPR 81/4885MCL1 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.